###begin article-title 0
Forty-Three Loci Associated with Plasma Lipoprotein Size, Concentration, and Cholesterol Content in Genome-Wide Analysis
###end article-title 0
###begin p 1
Conceived and designed the experiments: DI Chasman, G Pare, S Mora. Performed the experiments: AN Parker. Analyzed the data: DI Chasman, G Pare, JC Hopewell, Gina Peloso, S Ripatti. Contributed reagents/materials/analysis tools: DI Chasman, G Pare, JC Hopewell, R Clarke, LA Cupples. A Hamsten, S Kathiresan, A Malarstig, JM Ordovas, S Ripatti, AN Parker, JP Miletich, PM Ridker. Wrote the paper: DI Chasman, S Mora, JC Hopewell, G Peloso, R Clarke, LA Cupples, A Hamsten, S Kathiresan, A Malarstig, JM Ordovas, S Ripatti, AN Parker, JP Miletich, PM Ridker. Made comments on the manuscript: A Hamsten.
###end p 1
###begin p 2
###xml 685 686 685 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 691 693 691 693 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 735 745 735 745 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCCB/STAG1</italic>
###xml 756 766 756 766 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GMPR/MYLIP</italic>
###xml 777 782 777 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BTNL2</italic>
###xml 794 799 794 799 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLF14</italic>
###xml 818 824 818 824 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JMJD1C</italic>
###xml 836 840 836 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBF2</italic>
###xml 861 881 861 881 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 900 905 900 905 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WIPI1</italic>
###xml 1132 1135 1132 1135 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 1162 1166 1162 1166 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 1204 1208 1204 1208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 1338 1342 1338 1342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 1357 1366 1357 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC-APOE</italic>
###xml 589 594 <span type="species:ncbi:9606">women</span>
###xml 604 609 <span type="species:ncbi:9606">Women</span>
While conventional LDL-C, HDL-C, and triglyceride measurements reflect aggregate properties of plasma lipoprotein fractions, NMR-based measurements more accurately reflect lipoprotein particle concentrations according to class (LDL, HDL, and VLDL) and particle size (small, medium, and large). The concentrations of these lipoprotein sub-fractions may be related to risk of cardiovascular disease and related metabolic disorders. We performed a genome-wide association study of 17 lipoprotein measures determined by NMR together with LDL-C, HDL-C, triglycerides, ApoA1, and ApoB in 17,296 women from the Women's Genome Health Study (WGHS). Among 36 loci with genome-wide significance (P<5x10-8) in primary and secondary analysis, ten (PCCB/STAG1 (3q22.3), GMPR/MYLIP (6p22.3), BTNL2 (6p21.32), KLF14 (7q32.2), 8p23.1, JMJD1C (10q21.3), SBF2 (11p15.4), 12q23.2, CCDC92/DNAH10/ZNF664 (12q24.31.B), and WIPI1 (17q24.2)) have not been reported in prior genome-wide association studies for plasma lipid concentration. Associations with mean lipoprotein particle size but not cholesterol content were found for LDL at four loci (7q11.23, LPL (8p21.3), 12q24.31.B, and LIPG (18q21.1)) and for HDL at one locus (GCKR (2p23.3)). In addition, genetic determinants of total IDL and total VLDL concentration were found at many loci, most strongly at LIPC (15q22.1) and APOC-APOE complex (19q13.32), respectively. Associations at seven more loci previously known for effects on conventional plasma lipid measures reveal additional genetic influences on lipoprotein profiles and bring the total number of loci to 43. Thus, genome-wide associations identified novel loci involved with lipoprotein metabolism-including loci that affect the NMR-based measures of concentration or size of LDL, HDL, and VLDL particles-all characteristics of lipoprotein profiles that may impact disease risk but are not available by conventional assay.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 805 810 <span type="species:ncbi:9606">women</span>
###xml 841 846 <span type="species:ncbi:9606">Women</span>
Genome-wide association studies (GWAS) of plasma lipoprotein fractions hold great promise for understanding lipid metabolism and its central role in cardiovascular disease and related disorders. Conventional assays for lipoprotein status determine total cholesterol content of low- or high-density lipoprotein particles (LDL-C or HDL-C, respectively) or total plasma triglyceride content (as an estimate of very-low density lipoprotein particle concentration [VLDL]). All three measures have been targets for recent GWAS. However, a more precise target for GWAS of lipoprotein metabolism would be the concentration of the individual lipoprotein particles according to class (LDL, HDL, VLDL) and size (small, medium, and large), all of which can be measured by NMR-based methods. In a population of 17,296 women of European ancestry from the Women's Genome Health Study, we have performed a GWAS for 22 lipoprotein measures derived from NMR-based and conventional assays. We find 43 genetic loci involved in lipoprotein metabolism, including 10 novel loci. The results offer a clearer picture of common genetic influences on lipoprotein metabolism than available previously, including genetic effects on the distribution of LDL, HDL, and VLDL particle size, as well as on IDL and VLDL particle concentration, neither of which can be assessed by conventional measures.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 441 444 441 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Austin1">[1]</xref>
###xml 445 448 445 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Stampfer1">[2]</xref>
###xml 564 567 564 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan1">[3]</xref>
###xml 634 637 634 637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Mora1">[4]</xref>
Standard measures of plasma lipoprotein concentration do not reveal heterogeneity in the size of lipoprotein particles or their content of cholesterol and triglycerides. Yet recognizing this heterogeneity may be essential for understanding qualitative differences in lipid metabolism among individuals. Some reports identify a pattern in the size distribution of lipoprotein sub-fractions as intimately connected with coronary heart disease [1],[2]. Related findings identify a link between lipoprotein profile and metabolic syndrome, and by inference to diabetes [3]. While these observations remain controversial for prognostic use [4], they point to alterations in lipoprotein metabolism in disease.
###end p 6
###begin p 7
###xml 1230 1233 1230 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan2">[5]</xref>
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Tanaka1">[13]</xref>
The variation in particle size and lipid content can be quantified accurately by NMR-based methods that determine lipoprotein particle concentration according to lipid class and particle size. Thus, NMR methods can measure concentration of large and small low density lipoprotein (LDL) particles as well as concentration of the related intermediate density lipoprotein (IDL) particles, and similarly concentration of small, medium, and large high density lipoprotein (HDL) or very low density lipoprotein (VLDL) particles. HDL and LDL particle concentration can also be estimated by chemical measures of apolipoprotein A1 (ApoA1) and apolipoprotein B (ApoB) protein concentration, respectively, but neither these assays nor other standard clinical assays provide information about particle size distribution, and consequently the apportionment of cholesterol and triglycerides to different sized particles. The greater precision in characterizing lipoprotein profiles using NMR-based techniques provides an opportunity for correspondingly greater detail in understanding lipid metabolism, for example by genome-wide genetic analysis, as has been done recently for plasma concentration LDL-C, HDL-C, triglycerides, ApoA1, and ApoB [5]-[13].
###end p 7
###begin title 8
Results
###end title 8
###begin title 9
Genome-wide association analysis of 22 NMR-based and conventional lipoprotein fractions
###end title 9
###begin p 10
###xml 65 72 65 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t001">Table 1</xref>
###xml 297 298 297 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 303 305 303 305 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 409 416 409 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 733 740 733 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t001">Table 1</xref>
###xml 985 990 985 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCA1</italic>
###xml 1282 1289 1282 1289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 1370 1371 1370 1371 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1378 1380 1378 1380 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 1504 1505 1504 1505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1510 1512 1510 1512 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1560 1568 1560 1568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s005">Table S1</xref>
###xml 18 30 <span type="species:ncbi:9606">participants</span>
###xml 601 613 <span type="species:ncbi:9606">participants</span>
###xml 719 731 <span type="species:ncbi:9606">participants</span>
Among 17,296 WGHS participants with confirmed European ancestry (Table 1), we performed genome-wide association analysis assuming an additive genetic model for 22 plasma lipoprotein measures determined either by NMR methods or by standard clinical assay. On the basis of genome-wide significance (P<5x10-8), genetic variation at total of 31 loci was associated with at least one of the lipoprotein fractions (Table 2). Thirty of these 31 loci derive from analysis in the whole sample, while the remaining locus was identified with genome-wide significance in a subset of 12,489 (72%) strictly fasting participants, for whom there were small but significant differences in lipoprotein profiles compared with non-fasting participants (Table 1). Nearly all of the associations with genome-wide significance level in the fasting subsample also had genome-wide significance in the larger, better powered whole sample. One exception was the genome-wide significant association with ApoA1 at ABCA1 (9q31.1), a locus that was identified in the whole sample on the basis of genome-wide significant associations with HDL-C and medium HDL particles but not for ApoA1. The other was an association with mean VLDL size at 8p23.1, a locus that appears only in analysis in the fasting sub-sample (Table 2). These additional associations remain strongly suggestive in the whole sample (P<1.6x10-5) even though they do not reach genome-wide significance. Statistics for the most significant genome-wide associations with P<5x10-8 at each of the candidate loci are shown in the Table S1.
###end p 10
###begin title 11
WGHS population.
###end title 11
###begin p 12
Clinical characteristics are given as number (fraction) or median (interquartile range). Lipoprotein measures are given as median (interquartile range).
###end p 12
###begin p 13
p<0.001 for comparison of non-fasting (N = 4,807) fasting (N = 12,489) samples.
###end p 13
###begin p 14
HRT is abbreviation for hormone replacement therapy.
###end p 14
###begin p 15
lipid lowering treatment.
###end p 15
###begin title 16
###xml 74 76 74 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
Loci and candidate genes with genome-wide significant associations (p<5x10-8) for 22 lipoprotein measures.
###end title 16
###begin p 17
LDL = low density lipoprotein, IDL = intermediate density lipoprotein, HDL = high density lipoprotein, VLDL = very low density lipoprotein, APOB = apolipoprotein B, APOA1 = apolipoprotein A1.
###end p 17
###begin p 18
X:L = large particles, X:M = medium particles, X:S = small particles, X:Z = mean particle size, X:T total particles, X:N = assay by NMR, X-C = cholesterol.
###end p 18
###begin p 19
Bold type face indicates novel loci.
###end p 19
###begin p 20
###xml 137 144 137 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 175 185 175 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCCB/STAG1</italic>
###xml 197 202 197 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BTNL2</italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLF14</italic>
###xml 233 252 233 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC9/DNAH10/ZNF664</italic>
###xml 267 272 267 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WIPI1</italic>
###xml 294 303 294 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s001">Figure S1</xref>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLF14</italic>
###xml 583 602 583 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC9/DNAH10/ZNF664</italic>
###xml 890 893 890 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Willer1">[6]</xref>
Seven of the 31 unique loci reveal novel genome-wide significant associations with the plasma lipoprotein fractions (see bold font type, Table 2). The associations at 3q22.3 (PCCB/STAG1), 6p21.32 (BTNL2), 7q32.2 (KLF14), 12q24.31.B (CCDC9/DNAH10/ZNF664) and 17q24.2 (WIPI1) are all near genes (Figure S1), while genome-wide significant associations at the remaining two novel loci, 8p23.1 and 12q23.2 are remote (i.e. >150kb) from known genic regions. Among the standard clinical measures LDL-C, HDL-C, and triglycerides only, novel genome-wide loci were found at KLF14 (7q32.2) and CCDC9/DNAH10/ZNF664 (12q24.31.B), both for triglycerides. The association at the novel locus 8p23.1 (which differentiated the fasting sample from the whole sample on the basis of mean VLDL particle size) is over 1.8 Mb from a recently described association at 8p23.1 between SNP rs7819412 and triglycerides [6].
###end p 20
###begin p 21
###xml 119 128 119 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s001">Figure S1</xref>
###xml 199 204 199 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA2</italic>
###xml 234 238 234 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB</italic>
###xml 249 256 249 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG5/8</italic>
###xml 265 270 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HMGCR</italic>
###xml 281 284 281 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 295 303 295 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA1-A5</italic>
###xml 315 320 315 320 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCA1</italic>
###xml 331 338 331 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FADS1-3</italic>
###xml 350 354 350 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 366 370 366 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CETP</italic>
###xml 380 384 380 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 396 400 396 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 416 425 416 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC-APOE</italic>
###xml 450 454 450 454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PLTP</italic>
###xml 516 519 516 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABO</italic>
###xml 623 627 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Oliver1">[14]</xref>
###xml 628 632 628 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Langman1">[15]</xref>
###xml 770 777 770 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ANGPTL3</italic>
###xml 788 813 788 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CELSR2/MYBPHL/PSRC1/SORT1</italic>
###xml 824 828 824 828 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 839 845 839 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLXIPL</italic>
###xml 861 866 861 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRIB1</italic>
###xml 878 883 878 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNF1A</italic>
###xml 902 907 902 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNF4A</italic>
###xml 939 951 939 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">COBLL1/GRB14</italic>
###xml 1054 1058 1054 1058 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker1">[16]</xref>
###xml 1202 1207 1202 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GRB14</italic>
###xml 1270 1274 1270 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Daly1">[17]</xref>
###xml 1275 1279 1275 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Depetris1">[18]</xref>
###xml 1406 1414 1406 1414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s005">Table S1</xref>
###xml 1114 1119 <span type="species:ncbi:9606">women</span>
###xml 1125 1128 <span type="species:ncbi:9606">men</span>
The remaining 24 unique loci suggested genes recognized for a diversity of roles in lipid metabolism, broadly defined (Figure S1). Thus, SNPs with genome-wide significance, were confirmed in or near PCSK9 (at 1p32.3), APOA2 (1q23.3), APOB (2p24.1), ABCG5/8 (2p21), HMGCR (5q13.3), LPL (8p21.3), APOA1-A5 (11q23.3), ABCA1 (9q31.1), FADS1-3 (11q12.2), LIPC (15q22.1), CETP (16q13), LIPG (18q21.1), LDLR (19p13.2), the APOC-APOE complex (19q13.32), and PLTP (20q13.12). Similarly, association at 9q34.2 implicating the ABO gene recapitulates and extends the known association between blood group antigen and total cholesterol [14],[15]. Less well characterized genic regions, which nonetheless have been validated recently for roles in lipid metabolism, were confirmed for ANGPTL3 (1p31.3), CELSR2/MYBPHL/PSRC1/SORT1 (1p13.3), GCKR (2p23.3), MLXIPL (7q11.23), and TRIB1 (8q24.13), HNF1A (12q24.31.A), and HNF4A (20q13.12). The association at COBLL1/GRB14 (2q24.3) with HDL-C was recently described elsewhere in this same cohort and validated by replication [16]. The previous study found much stronger association in women than men, suggesting a potential interaction with gender. At this locus, the gene GRB14 is thought to inhibit receptors in the insulin receptor class [17],[18]. The current analysis extends associations at this locus to concentrations of LDL, HDL, and VLDL particles according to size (Table S1).
###end p 21
###begin p 22
###xml 77 85 77 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s006">Table S2</xref>
###xml 232 241 232 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s001">Figure S1</xref>
###xml 272 276 272 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOB</italic>
###xml 413 421 413 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s005">Table S1</xref>
###xml 582 583 582 583 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 741 742 741 742 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 869 878 869 878 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000730-g001">Figure 1A</xref>
###xml 940 941 940 941 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 969 980 969 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5-APOA1</italic>
###xml 1087 1092 1087 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA5</italic>
###xml 1145 1150 1145 1150 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA1</italic>
###xml 1201 1210 1201 1210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000730-g001">Figure 1B</xref>
Consistent with a high degree of correlation among the lipoprotein measures (Table S2), the rank order by p-value among the highly significant SNPs was similar for each measure with at least one genome-wide significant association (Figure S1). A notable exception was the APOB gene (2p24.1), where the ordering of the p-values, conditional analysis, and patterns of linkage disequlibrium (LD) among the top SNPs (Table S1) revealed three classes of associations. One class included VLDL-related fractions, triglycerides, and mean LDL size for which either rs673548 or rs676210 (LD r2 = 1.0) had the strongest association; a second class included ApoB, large LDL particles, and total LDL particles for which either rs1713222 or rs506585 (LD r2 = 0.5) had the strongest association; and a final class including only LDL-C for which rs137117 was most strongly associated (Figure 1A). Between SNPs in different classes, maximum LD ranged from r2 = 0.04-0.11. Similarly, at APOA5-APOA1 (11q23.3), p-values revealed two classes of associations seemingly segregating between effects nearer the APOA5 gene involving triglycerides and effects nearer the APOA1 gene involving HDL related lipoprotein fractions (Figure 1B).
###end p 22
###begin title 23
Loci with distinct classes of SNP associations among lipoprotein fractions with genome-wide significance.
###end title 23
###begin p 24
###xml 84 88 84 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-McVean1">[41]</xref>
(A) APOB locus (2p24.1), (B) APOA1-A5 locus (11q23.3). Recombination rates are from [41].
###end p 24
###begin p 25
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Tsai1">[19]</xref>
###xml 257 261 257 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Barlera1">[20]</xref>
###xml 641 649 641 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s007">Table S3</xref>
###xml 682 690 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s008">Table S4</xref>
###xml 774 779 774 779 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCA1</italic>
###xml 858 859 858 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1477 1478 1477 1478 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1485 1493 1485 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s007">Table S3</xref>
###xml 1699 1709 1699 1709 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCCB/STAG1</italic>
###xml 1720 1725 1720 1725 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BTNL2</italic>
###xml 1737 1742 1737 1742 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLF14</italic>
###xml 1764 1768 1764 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan3">[10]</xref>
###xml 1815 1825 1815 1825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCCB/STAG1</italic>
###xml 1839 1844 1839 1844 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BTNL2</italic>
###xml 1906 1913 1906 1913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t003">Table 3</xref>
###xml 2369 2373 2369 2373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker2">[21]</xref>
###xml 2502 2503 2502 2503 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2508 2511 2508 2511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;15</sup>
###xml 2543 2563 2543 2563 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 2581 2586 2581 2586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WIPI1</italic>
###xml 2653 2660 2653 2660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t003">Table 3</xref>
###xml 2787 2791 2787 2791 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Aulchenko1">[11]</xref>
###xml 3322 3329 3322 3329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t003">Table 3</xref>
###xml 3394 3402 3394 3402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s005">Table S1</xref>
###xml 127 139 <span type="species:ncbi:9606">participants</span>
Large, well-characterized cohorts with NMR-based measurement of lipoprotein fractions are scant, but sub-samples of about 2700 participants in the Framingham Heart Study Offspring cohort (FHS) [19] and about 2000 total CHD cases and controls from PROCARDIS [20] had both the NMR-based lipoprotein measures and genome-wide genetic data already determined. Among all candidate loci, concordance of direction of effects was observed respectively at 124 out of 146 (84%) [84% in fasting sub-sample] and 125 out of 133 (94%) [99% in fasting sub-sample] of the candidate associations for which there was genotype information in FHS and PROCARDIS (Table S3 [whole WGHS sample candidates], Table S4 [fasting WGHS subsample candidates]). For each of the previously known loci except ABCA1 (9q31), at least one of the candidate associations was nominally significant (P<0.05, two-sided) in at least one of the replication cohorts or in analysis combining p-values from the two replication cohorts when effect estimates (beta coefficients) indicated trends in lipoprotein measure consistent with the effects observed in the WGHS. Among the 7 novel loci from the primary analysis only, where the effect estimates for the WGHS were generally smaller and power for replication was less, concordance of the direction of effects remained high for the PROCARDIS sample [86% (25/29)], although only modest for the FHS sample [58% (22/38)], but these associations were not significant (two-sided P>0.05; Table S3). However, a recent genome-wide meta-analysis of LDL-C, HDL-C, and triglycerides found significant, but not genome-wide significant, associations among these fractions with candidate SNPs from the WGHS at PCCB/STAG1 (3q22.3), BTNL2 (6p21.32), KLF14 (7q32.2), and 8p23.1 [10], although the significant SNP associations at PCCB/STAG1 (3q22.3) and BTNL2 (6p21.32) were not fully concordant between the two studies (Table 3). Independent evidence for functional consequence of the candidate SNP (rs10778213) at 12q23.2 is its genome-wide significant association in a smaller sample from the WGHS with plasma C-reactive protein (CRP), a biomarker of inflammation that is slightly correlated if at all with the two HDL measures associated at this locus (total HDL particle concentration [HDL:T], Spearman r = 0.22; HDL cholesterol estimated by the NMR [HDL:N], Spearman r = -0.04) [21]. With the larger sample of WGHS genotype information in the current study, the association with plasma CRP is more significant (P<5x10-15). Finally, the associations at CCDC92/DNAH10/ZNF664 [12q24.31.B] and WIPI1 (17q24.2) were not confirmed either in the meta-analysis shown in Table 3 or in a second genome-wide meta-analysis of LDL-C, HDL-C, and triglycerides that also evaluated gender stratified association [11] (data not shown). Nevertheless, ongoing genotyping in the WGHS of an additional 4639 samples (3305 with fasting status) completed subsequent to the main analysis provided significant support for these last two loci on the basis of internal replication, as well as significant or borderline significant support for four others, confirming directions of effects for all novel candidate associations, and leading to smaller p-values in analysis combining the main WGHS sample with the additional samples for all but three entries in Table 3 and at least one lipoprotein measure for each locus (compare to Table S1).
###end p 25
###begin title 26
Replication of associations with LDL-C, HDL-C, and triglycerides at novel loci.
###end title 26
###begin p 27
###xml 68 72 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan3">[10]</xref>
Meta-analysis of LDL-C, HDL-C, and TG among 12 European populations [10].
###end p 27
###begin p 28
###xml 244 252 244 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Tables 2</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s006">S2</xref>
Most significant genome-wide SNP and lipoprotein fraction(s) association at locus for tests among the 22 lipoprotein fractions. (+/-) indicates trend of fraction with increasing copies of the minor allele (same as sign of beta coefficient, see Tables 2 and S2).
###end p 28
###begin p 29
P-value (two-sided) for association in additional 4639 (all) or 3305 (fasting) samples from the WGHS (internal replication). All association trends were consistent with discovery sample. Combining these new samples with the original discovery samples leads to p-values for the extended WGHS sample. Bold font indicates p-value smaller than in main discovery sample.
###end p 29
###begin p 30
###xml 203 204 203 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
P-value and trend (+/-) for association of increasing copies of the minor allele with indicated lipoprotein fraction in either WGHS or the meta-analysis. n.s. in WGHS analysis indicates not significant (P>0.05).
###end p 30
###begin p 31
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker2">[21]</xref>
Genome-wide significant association with plasma C-reactive protein in the WGHS [21].
###end p 31
###begin title 32
Magnitudes of genetic effects
###end title 32
###begin p 33
###xml 362 370 362 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000730-g002">Figure 2</xref>
###xml 372 380 372 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s009">Table S5</xref>
###xml 386 394 386 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s010">Table S6</xref>
###xml 427 436 427 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC-APOE</italic>
###xml 739 747 739 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s009">Table S5</xref>
###xml 752 760 752 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s010">Table S6</xref>
###xml 916 921 916 921 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOA2</italic>
###xml 958 963 958 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WIPI1</italic>
###xml 1368 1377 1368 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s002">Figure S2</xref>
###xml 1379 1388 1379 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s003">Figure S3</xref>
###xml 1505 1510 1505 1510 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNF1A</italic>
###xml 1512 1516 1512 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LDLR</italic>
###xml 1518 1525 1518 1525 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ABCG5/8</italic>
###xml 1527 1532 1527 1532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCSK9</italic>
###xml 1538 1561 1538 1561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CELSR2/PSRC1/SARS/SORT1</italic>
To assess the contribution of common genetic variation at each of the candidate loci to each of the adjusted lipoprotein fractions, we constructed regression models by stepwise selection of SNPs in the vicinity of the primary genome-wide significant associations. Most of these models explain less than 1% of the variation in the adjusted lipoprotein fractions (Figure 2, Table S5, and Table S6). The top three effects, all at APOC-APOE complex (19q13.32), explain 8.9%, 8.4%, and 7.1% of the variance in ApoB particle concentration, the related total LDL particle concentration, and LDL-C, respectively. Fasting status had an influence on retention of SNPs in the model selection procedure, but only for loci with modest effects (Compare Table S5 and Table S6). There were no genetic contributions remaining from the model selection procedure for any of LDL-C, HDL-C, triglycerides, ApoA1, or ApoB concentration at APOA2 (1q23.3) in the whole sample and at WIPI1 (17q24.2) in the fasting subsample, suggesting that these loci would not have been identified for genome-wide association with the five conventional lipoprotein fractions even in a much larger sample with the genome-wide SNP genotyping panel used in this study. Clustering loci on the basis of the profile of associated lipoprotein fractions suggests sub-groups of loci with related patterns of effects (Figure S2, Figure S3), perhaps suggesting distinct but possibly overlapping biological pathways for lipoprotein metabolism. For example, HNF1A, LDLR, ABCG5/8, PCSK9, and CELSR2/PSRC1/SARS/SORT1 largely share associations with IDL, small VLDL, total VLDL large LDL, LDL-C, total LDL, and ApoB.
###end p 33
###begin title 34
Variance explained in adjusted lipoprotein measures by common variation at the candidate loci by SNPs retained in model selection procedures.
###end title 34
###begin p 35
###xml 9 18 9 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s002">Figure S2</xref>
###xml 23 32 23 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s003">Figure S3</xref>
See also Figure S2 and Figure S3.
###end p 35
###begin p 36
###xml 153 160 153 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t004">Table 4</xref>
###xml 290 297 290 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t004">Table 4</xref>
###xml 381 389 381 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s011">Table S7</xref>
###xml 597 604 597 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t004">Table 4</xref>
The total genetic effects for each lipoprotein determined by summing over the effects at all loci ranged from 2.1% for mean VLDL size to 17.2% for ApoB (Table 4). The effects were not substantially different when the entire model selection procedure was performed in the fasting subsample (Table 4), and only slightly smaller in general among the unadjusted lipoprotein fractions (Table S7). Notably, the common genetic variation in this study at the genome-wide loci had a greater total effect on mean particle size than on standard clinical cholesterol measures for HDL but not for LDL or VLDL (Table 4).
###end p 36
###begin title 37
Proportion (%) variance in fully adjusted lipoprotein fractions explained by common variation at candidate loci.
###end title 37
###begin title 38
Secondary genome-wide analysis
###end title 38
###begin p 39
To examine the possibility that other loci might include SNPs with genome-wide significant association conditional on effects at the primary loci, we adjusted the primary lipoprotein fraction measurements (which were already adjusted for clinical covariates) for SNPs retained by the model selection procedure at the candidate loci, and repeated the genome-wide association testing. Quantile-quantile analysis confirmed that all of the excess of extremely small p-values in the original analysis could be explained by the variation at the candidate loci (not shown). Similarly, genotype-based statistical models (as opposed to the allele-based additive models used in the primary analysis) did not reveal other loci with genetic influences at the genome-wide significance level in the whole sample.
###end p 39
###begin p 40
###xml 774 782 774 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s012">Table S8</xref>
###xml 1123 1126 1123 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPA</italic>
###xml 1137 1141 1137 1141 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCAT</italic>
###xml 1157 1161 1157 1161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOH</italic>
###xml 1374 1378 1374 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GMPR</italic>
###xml 1382 1387 1382 1387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MYLIP</italic>
###xml 1402 1408 1402 1408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JMJD1C</italic>
###xml 1573 1580 1573 1580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t005">Table 5</xref>
###xml 1582 1586 1582 1586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan3">[10]</xref>
###xml 1864 1871 1864 1871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t005">Table 5</xref>
###xml 1890 1896 1890 1896 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">JMJD1C</italic>
###xml 2251 2259 <span type="species:ncbi:521149|species:ncbi:37083|species:ncbi:132103|species:ncbi:302407|species:ncbi:640495|species:ncbi:286093|species:ncbi:107284|species:ncbi:6587|species:ncbi:110886">e. minor</span>
While we adjusted the lipoprotein measures with a full set of clinical characteristics to reduce variance and enhance power in the primary analysis, it remained possible that relevant SNPs would be overlooked if they acted through effects on the adjustment covariates. Similarly, subtle effects on the association estimates due to non-normality of the (possibly log-transformed) adjusted lipoprotein measures or due sub-European population stratification might confound hypothesis testing. To evaluate whether our discovery procedure was robust, we performed secondary analyses repeating the entire genome-wide discovery procedure for alternative nested subsets of clinical covariates with and without further adjustment for population structure and quantile normalization (Table S8). Comparing the full adjustment procedure to alternatives using either a reduced set of clinical covariates or age only, with or without additional adjustment for potential sub-European population stratification and quantile normalization yielded further genome-wide significant associations at three loci with known lipid metabolic genes, LPA (6q25.3), LCAT (16q22.1), and APOH (17q24.2), and two additional loci, 6p22.3 and 10q21.3. All of the additional loci were present in the age-adjusted analysis. Associations at 6p22.3 and 10q21.3 appear to be novel and implicate, respectively the GMPR or MYLIP genes and the JMJD1C gene. The lead SNPs at each of these loci were significantly associated with at least one of LDL-C, HDL-C or triglycerides in the recently published meta-analysis (Table 5) [10]. Similarly, in internal replication among the additional 4639 WGHS samples with genotype available after the main analysis was complete, associations at the candidate SNPs were all significant and the trends of effects were all consistent with effects in the discovery sample (Table 5). We note that at JMJD1C (10q21.3), the candidate SNPs have minor allele frequency near 0.5, and that available data does not allow us to determine whether the differences in the direction of the minor allele effect on VLDL fractions in the WGHS and triglycerides in the previously published replication study are truly physiological or rather that the frequency of the coded (i.e. minor) allele from the WGHS is greater than 0.5 in the replication cohort resulting in an opposite sign of the effect estimates.
###end p 40
###begin title 41
###xml 44 46 44 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 126 127 126 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt113">*</xref>
Genome-wide significant associations (p<5x10-8) at novel loci in analysis of age-adjusted and full-plus-triglycerides-adjusted* lipoprotein fractions.
###end title 41
###begin p 42
###xml 112 133 112 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
Full adjustment procedure (age, BMI, smoking status, menopausal status, use of hormone replacement therapy; see Materials and Methods) with addition of log-transformed triglyceride levels.
###end p 42
###begin p 43
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan3">[10]</xref>
###xml 126 127 126 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Most significant association among LDL-C, HDL-C, and triglycerides (TG) in recent meta-analysis [10]. n.s. = not significant (P>0.05).
###end p 43
###begin p 44
###xml 19 26 19 26 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
Abbreviation as in Table 2.
###end p 44
###begin p 45
P-value (two-sided) for association in additional 4639 samples from the WGHS. All association trends were consistent with discovery sample. Combining these new samples with the original discovery samples leads to p-values for the extended WGHS sample.
###end p 45
###begin p 46
###xml 288 295 288 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t005">Table 5</xref>
###xml 300 308 300 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s012">Table S8</xref>
###xml 429 433 429 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBF2</italic>
###xml 626 627 626 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Since lipoprotein particle size is closely related to triglyceride content, we also performed secondary analysis examining genome-wide significant associations after adjustment of the lipoprotein fractions by the full set of clinical covariates and (log-transformed) triglyceride levels (Table 5 and Table S8). This analysis identified only one new genome-wide significant association. At 11p15.4, rs7938647 in the intron of the SBF2 gene was associated with full-plus-triglyceride adjusted total HDL particle concentration. Again, internal replication provided support for this association although there was no association (P>0.05) with LDL-C, HDL-C, or triglycerides in the recent meta-analysis for replication.
###end p 46
###begin title 47
Associations distinguishing NMR-based from conventional lipoprotein measures
###end title 47
###begin p 48
###xml 291 299 291 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000730-g002">Figure 2</xref>
###xml 301 308 301 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 310 318 310 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s005">Table S1</xref>
###xml 341 345 341 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 479 482 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;20</sup>
###xml 611 620 611 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC-APOE</italic>
###xml 708 712 708 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 824 827 824 827 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;12</sup>
###xml 829 837 829 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s005">Table S1</xref>
Among its unique characteristics, the NMR-based methodology provides information about IDL and VLDL particle concentration, both aspects of lipoprotein profiles that are difficult to measure by conventional methods. For IDL, genetic associations were observed at many of the candidate loci (Figure 2, Table 2, Table S1) and most strongly at LIPC (15q22.1), where rs1532085 had an estimated 0.11 nmol/l shift in particle concentration for each copy of the minor allele (p = 1.5x10-20). For total VLDL concentration, association with genetic variation was observed at many loci but none more strongly than at the APOC-APOE complex where rs439401, which is in perfect LD with rs7412 (the SNP that distinguishes APOE alleles E2 and E3), had an estimated -2.4nmol/l shift in concentration per copy of the minor allele (p = 2.1x10-12; Table S1).
###end p 48
###begin p 49
###xml 373 380 373 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
###xml 382 391 382 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s004">Figure S4</xref>
###xml 479 486 479 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 581 587 581 587 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLXIPL</italic>
###xml 599 602 599 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 613 633 613 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 652 656 652 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 805 825 805 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 965 971 965 971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLXIPL</italic>
###xml 983 986 983 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 997 1001 997 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 1051 1071 1051 1071 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 1091 1100 1091 1100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s004">Figure S4</xref>
###xml 1177 1180 1177 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 1194 1198 1194 1198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 1268 1274 1268 1274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLXIPL</italic>
###xml 1289 1309 1289 1309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 1401 1408 1401 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 1503 1507 1503 1507 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 1562 1570 1562 1570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000730-g002">Figure 2</xref>
###xml 1572 1579 1572 1579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
###xml 1644 1647 1644 1647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 1658 1678 1658 1678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 1697 1701 1697 1701 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 2011 2018 2011 2018 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
Loci strongly affecting the relative concentration of NMR-based estimates of small, medium, and large particle size could be identified on the basis of genome-wide effects on mean particle size, and these associations were of special interest when there was no accompanying association with the corresponding cholesterol measure retained in the model selection procedures (Table 6, Figure S4). For LDL, mean particle size was associated with genome-wide significance at 12 loci (Table 2), among which the model selection procedures failed to identify any association with LDL-C at MLXIPL (7q11.23), LPL (8p21.3), CCDC92/DNAH10/ZNF664 (12q24.31.B), and LIPG (18q21.1). These loci implicate genes related to glucose or triglyceride metabolism as well as unrecognized biological function at one novel locus (CCDC92/DNAH10/ZNF664 [12q24.31.B]). The associations with mean LDL particle size were a consequence of strong inverse effects on large and small LDL particles (MLXIPL [7q11.23], LPL [8p21.3], LIPG [18q21.1]) or of exclusive effects on small LDL (CCDC92/DNAH10/ZNF664 [12q24.31.B]) [see Figure S4]. In the fasting subsample, the associations with the NMR based measures at LPL (8p21.3) and LIPG (18q21.1) also met genome-wide significance, but the associations at MLXIPL (7q11.23) and CCDC92/DNAH10/ZNF664 (12q24.31.B) did not. For HDL, 9 loci had genome-wide significance for mean particle size (Table 2), among which the clinical measure of HDL-C was not associated with genetic variation only at GCKR (2p23.3), as was also found in the fasting subsample (Figure 2, Table 6). The discordant effects on LDL size and cholesterol content at LPL (8p21.3), CCDC92/DNAH10/ZNF664 (12q24.31.B), and LIPG (18q21.1) but not those of HDL size and cholesterol content were independent of triglyceride level in as much as associations persisted in analysis that further adjusted the lipoprotein fractions for (log-transformed) triglycerides, although only at nominal significance rather than genome-wide significance (Table 6).
###end p 49
###begin title 50
###xml 47 48 47 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 55 57 55 57 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 175 176 175 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table-fn" rid="nt117">*</xref>
Loci with genome-wide significant association (P<5.0x10-8) for mean particle size but no associations in model selection procedures with cholesterol content or particle number*.
###end title 50
###begin p 51
###xml 4 13 4 13 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s004">Figure S4</xref>
See Figure S4 for effects of individual SNPs across lipoprotein measures.
###end p 51
###begin p 52
Bold typeface indicates differential associations for triglyceride adjusted fractions with at least nominal significance. w = whole sampe, f = fasting subsample.
###end p 52
###begin p 53
###xml 121 128 121 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
###xml 145 149 145 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 581 586 581 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">KLF14</italic>
###xml 597 604 597 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FADS1-3</italic>
###xml 616 636 616 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 654 658 654 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 789 794 789 794 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WIPI1</italic>
###xml 981 988 981 988 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 990 998 990 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000730-g002">Figure 2</xref>
###xml 1000 1009 1000 1009 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s004">Figure S4</xref>
###xml 1041 1044 1041 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 1138 1145 1138 1145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
###xml 1525 1532 1525 1532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
By the same standards, loci could be identified with effects on mean particle size but not total particle concentration (Table 6). Thus, SNPs at LIPC (15q22.1) and LIPG (18q21.1) had genome-wide significant associations for mean LDL particle size, but were null for particle concentration in model selection procedures in both the whole sample and the fasting subsample. These loci are characterized by genes known to influence triglyceride metabolism. Similarly, for HDL, comparison of associations with mean particle size and total particle concentration identified variation at KLF14 (7q32.2), FADS1-3 (11q12.2), CCDC92/DNAH10/ZNF664 (12q24.31.B) and LIPC (15q22.1), implicating roles for known lipid candidate genes as well as loci with unknown functions. Variation at the novel locus WIPI1 (17q24.2), while not affecting mean HDL particle size, was associated with the concentration of medium-sized HDL, but not large or small HDL, total HDL particle concentration, or HDL-C (Table 2, Figure 2, Figure S4). In addition, associations at LPL (8p21.3) in the fasting subsample distinguished total HDL particle concentration from HDL-C (Table 6). VLDL particle size but not concentration was influenced by variation at 8p23.1 in the fasting subsample but there were no genome-wide significant associations at this locus in the whole sample. Again, in triglyceride-adjusted analysis, discordant effects on mean particle size and total concentration persisted but at some of the candidate loci in the analysis of LDL and HDL (Table 6).
###end p 53
###begin title 54
Lipoprotein candidate loci from other genome-wide association studies
###end title 54
###begin p 55
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan3">[10]</xref>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Sabatti1">[12]</xref>
###xml 932 940 932 940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s013">Table S9</xref>
###xml 945 954 945 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s014">Table S10</xref>
###xml 969 975 969 975 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TMEM57</italic>
###xml 977 983 977 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 985 997 985 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TIMD4/HAVCR1</italic>
###xml 999 1015 999 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MADD/FOLH1/NR1H3</italic>
###xml 1017 1025 1017 1025 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MVK/MMAB</italic>
###xml 1027 1031 1027 1031 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCAT</italic>
###xml 1033 1052 1033 1052 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLIP2/PBX4/NCAN/SF4</italic>
###xml 1141 1145 1141 1145 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MAFB</italic>
###xml 1272 1278 1272 1278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 1295 1301 1295 1301 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GALNT2</italic>
###xml 1303 1319 1303 1319 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MADD/FOLH1/NR1H3</italic>
###xml 1321 1329 1321 1329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MVK/MMAB</italic>
###xml 1331 1350 1331 1350 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CLIP2/PBX4/NCAN/SF4</italic>
Recent genome-wide meta-analysis of lipoprotein LDL-C, HDL-C, and triglycerides identified and validated 17 loci that were not found at the genome-wide significance level in the current population [10]-[12] in spite of comparable statistical power. We examined SNPs within 100kb of each of these additional candidate loci to extend associations to each of the NMR-based lipoprotein fractions. The choice of a threshold p-value for significance is a controversial issue in these analyses: although all of the candidate loci had been validated previously, the current analysis was performed in the context of a genome-wide association study. We present all locus associations when statistical significance of Bonferroni corrected p-value for the most significant locus association was less than 0.05, accounting for the product of the number of lipoprotein fractions tested (22) and the number of locus SNPs considered (range 8-125) (Table S9 and Table S10). Seven loci (TMEM57, GALNT2, TIMD4/HAVCR1, MADD/FOLH1/NR1H3, MVK/MMAB, LCAT, CLIP2/PBX4/NCAN/SF4) met this criterion in the whole WGHS sample and, at the same standard, one more locus (MAFB) could be added in the fasting subsample. Among these loci, associations with lipoprotein size measures were found for LDL at GALNT2, and for HDL at GALNT2, MADD/FOLH1/NR1H3, MVK/MMAB, CLIP2/PBX4/NCAN/SF4. No associations at the stringent significance level were found with mean VLDL size or total IDL concentration. Associations with HDL and LDL total particle concentration were largely consistent with parallel associations with ApoA1 and ApoB respectively.
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 686 690 686 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCCB</italic>
###xml 704 711 704 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3B</italic>
###xml 1089 1093 1089 1093 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">SBF2</italic>
###xml 1105 1125 1105 1125 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CCDC92/DNAH10/ZNF664</italic>
###xml 1144 1149 1144 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WIPI1</italic>
###xml 1998 2002 1998 2002 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOH</italic>
###xml 2007 2011 2007 2011 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LCAT</italic>
###xml 60 65 <span type="species:ncbi:9606">Women</span>
###xml 930 933 <span type="species:ncbi:9606">men</span>
###xml 938 943 <span type="species:ncbi:9606">women</span>
By performing genome-wide association analysis among 17,296 Women with European ancestry for 22 NMR-based and conventional lipoprotein fractions, we identified 36 loci in the primary and secondary analyses for roles in lipoprotein metabolism, broadly defined. Ten of these loci have not been reported in other recent genome-wide association studies, including one identified only after adjustment for triglyceride levels. The functional bases for the associations are uncertain for five, including associations at 8p32.1 and 12q23.2 that map to intergenic regions. In spite of the high degree of correlation among some of the NMR-based and conventional measures, two of the novel loci (PCCB [3q22.3] and PPP1R3B [8p23.1]) could not have been found at the genome-wide significance standard solely with conventional measures (or their NMR-based equivalents) of lipoprotein profile in the WGHS. Replication in independent cohorts of men and women as well as other observations provided confirmatory evidence for candidate variation at all novel, although only through internal replication at SBF2 (11p15.4), CCDC92/DNAH10/ZNF664 (12q24.31.B), and WIPI1 (17q24.2). The failure of external replication to validate these two novel loci may simply reflect intrinsic differences from the WGHS in NMR-based assay protocols (FHS) or clinical features of the cohort (e.g. lipid lowering treatment in PROCARDIS) as well as limiting power; alternatively, the associations observed in the WGHS may not reflect true genetic effects. Among the primary loci, total genetic effects were largest and appreciable for ApoB, total LDL, and others. They were the smallest for mean VLDL size. While the heritability for the NMR-based fractions has not been thoroughly explored, the present analysis suggests some aspects of lipoprotein profiles may be much less affected by common genetic variation than others. Combining the 31 loci in the primary analysis, the five loci in the secondary analysis (three novel loci plus APOH and LCAT), and the seven previously recognized loci for which the WGHS extends associations to the NMR-based lipoprotein measures brings the total to 43 loci characterized by the present study.
###end p 57
###begin p 58
###xml 192 199 192 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
###xml 202 210 202 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A priori</italic>
###xml 443 446 443 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LPL</italic>
###xml 448 452 448 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPC</italic>
###xml 454 458 454 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LIPG</italic>
###xml 464 468 464 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 527 533 527 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MLXIPL</italic>
###xml 837 844 837 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
As important as the total number of candidate loci, some loci harbored variation exclusively correlated with the size of lipoprotein particles rather their cholesterol or total concentration (Table 6). A priori, one might have argued that triglyceride metabolic processes would be critical in this respect. This notion was confirmed by several candidate genes with known function in triglyceride metabolism, for example the enzymes encoded by LPL, LIPC, LIPG, and GCKR as well as the transcriptional regulatory protein encoded MLXIPL all have activities that may alter equilibrium pools of triglycerides and hence particle size or concentration. Other loci with only partly understood function were also identified, and these loci may now be further characterized through the current analysis. While it remains possible that the loci in Table 6 contain genetic variants not evaluated in this study and yet associated with cholesterol content or total particle concentration, the discordant effects on particle size compared with cholesterol or total particle concentration suggest biochemical pathways impinging on aspects of lipoprotein metabolism that are overlooked by standard clinical testing. To the extent that the pathophysiology of cardiovascular disease and related metabolic disorders, e.g. diabetes, is influenced by the distribution of lipoprotein particle size there may be therapeutic opportunities targeting the biochemical pathways identified by the discordant associations.
###end p 58
###begin p 59
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 93 95 93 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 241 262 241 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
###xml 461 469 461 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s006">Table S2</xref>
###xml 597 605 597 605 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pgen-1000730-g002">Figure 2</xref>
###xml 651 658 651 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t006">Table 6</xref>
###xml 683 684 683 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 689 691 689 691 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 911 912 911 912 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 917 919 917 919 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 1091 1092 1091 1092 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1097 1099 1097 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;7</sup>
###xml 1279 1280 1279 1280 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1285 1287 1285 1287 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
The procedures in the primary analysis enforced a genome-wide significance standard of P<5x10-8 for each lipoprotein measure. This standard was likely adequate for performing separate tests in the whole sample and the fasting subsample (see Materials and Methods) but does not explicitly address the multiplicity of testing the 22 lipoprotein measures at once. In part, the burden of significance is attenuated by correlations between the lipoprotein measures (Table S2), but the correlations are not exact and independent aspects of each measure are revealed by the diversity of effects shown in Figure 2 as well as by the discordant associations of Table 6. However, the choice of P<5x10-8 for genome-wide significance can be further justified by false discovery rate (FDR) analysis. For p-values from all of the lipoprotein measures considered at once, the conventional standard requiring FDR<0.05 implied a P<2x10-5, more than two order of magnitude less significant than the genome-wide p-value threshold. Similarly, among the individual lipoprotein measures, FDR<0.05 implied at worst P<7x10-7 for the case of IDL, still less significant than our genome-wide standard by over an order of magnitude. Thus, on a post-hoc basis, applying the conventional genome-wide standard P<5x10-8 for all fractions appears to have been justified.
###end p 59
###begin p 60
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BTNL2</italic>
###xml 402 406 402 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Simmonds1">[22]</xref>
###xml 407 411 407 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Valentonyte1">[24]</xref>
###xml 561 568 561 568 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B3GALT4</italic>
###xml 607 610 607 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Willer1">[6]</xref>
###xml 615 625 615 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAG1/PCCB</italic>
###xml 724 729 724 729 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">STAG1</italic>
###xml 805 809 805 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PCCB</italic>
###xml 961 965 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ravn1">[25]</xref>
###xml 1023 1030 1023 1030 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPP1R3B</italic>
###xml 1228 1233 1228 1233 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">WIPI1</italic>
###xml 1327 1331 1327 1331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-ProikasCezanne1">[26]</xref>
###xml 1578 1585 1578 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t005">Table 5</xref>
###xml 1630 1634 1630 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOH</italic>
###xml 1634 1638 1634 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Sanghera1">[27]</xref>
Four of the 10 novel loci (7 from primary analysis, 3 from secondary analysis) have functional links to lipoprotein metabolism or disease status, even if strict biochemical roles of the candidate genes and protein are not yet known. Variation at BTNL2 (6p21.32) has been associated with Grave's disease, multiple sclerosis, and sarcoidosis, apparently independent of the neighboring HLA class DR genes [22]-[24]. In addition, the lipoprotein association at this locus is within 780kb of a recently reported association of rs2254387 with LDL-C attributed to the B3GALT4 gene encoding a galactosyltransferase [6]. At STAG1/PCCB (3q22.3), the genome-wide significant association with small HDL particle concentration is in the STAG1 gene, but a more likely candidate for lipid metabolism may be the adjacent PCCB gene encoding the propionyl coenzyme A carboxylase beta subunit, in which substitutions cause Mendelian forms of proprionic acidemia (see, for example [25]). At 8p23.1, over 150kb from the candidate SNP rs983309, PPP1R3B encodes a phosphatase regulating glycogen phosphorylase, a plausible regulator of glucose and triglycerides. At 17q24.3, the connection to lipid metabolism can be made through an encoded domain of WIPI1 protein, the WD40 domain, which is a structural motif thought to interact with phospholipids [26]. The strongest association at this locus is over 2Mb away but statistically independent from the associations of rs1801689 with full-plus-triglyceride-adjusted total LDL particle concentration or rs2909207 with age-adjusted medium HDL particles (Table 5), both adjacent to the lipid candidate gene APOH[27]. The remaining six loci have intergenic status, or are proximal to genes with unresolved connections to lipoprotein metabolism.
###end p 60
###begin p 61
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker2">[21]</xref>
###xml 341 342 341 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 351 354 351 354 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;15</sup>
###xml 430 434 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GCKR</italic>
###xml 436 445 436 445 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOC-APOE</italic>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNF1A</italic>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker2">[21]</xref>
###xml 527 532 527 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HNF4A</italic>
###xml 647 654 647 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pgen-1000730-t002">Table 2</xref>
###xml 656 664 656 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s005">Table S1</xref>
###xml 873 877 873 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker3">[28]</xref>
Nevertheless, association at one of these six loci, 12q23.2, between rs7307277 and HDL-C measured by NMR involves the same SNP we previously reported for genome-wide significant association with plasma C-Reactive Protein (CRP) in a subset of the current population [21], an association that remains highly significant in the current sample (P = 4.5x10-15). Previous reports, including our own, had also identified associations at GCKR, APOC-APOE complex, and HNF1A with both lipid fractions and CRP [21]. We could now also add HNF4A to this list since rs4810479 at 20q13.12.A is associated in the WGHS with both CRP and the lipoprotein fractions (Table 2, Table S1). These links between lipoprotein metabolism and CRP are particularly intriguing given the efficacy of lipid lowering therapy with statins among individuals identified as at risk on the basis of elevated CRP [28].
###end p 61
###begin p 62
The etiology of cardiovascular disease is complex, and is believed to include an interplay between cell-based processes, including inflammation, and blood components, including lipoprotein fractions. The latter aspect may be summarized by clinical measures of cholesterol or triglycerides, or by ApoA1 and ApoB concentration. However, none of these aggregate measures reflects the full diversity of lipoprotein species in blood. The current investigation not only identifies novel loci for lipid metabolism in general, but may also help delineate the impact of lipoprotein metabolic genes on lipoprotein profile viewed with the highest resolution currently available.
###end p 62
###begin title 63
Materials and Methods
###end title 63
###begin title 64
Ethics statement
###end title 64
###begin p 65
All analyses were performed with approval of local institutional review boards (IRBs).
###end p 65
###begin title 66
Study populations
###end title 66
###begin p 67
###xml 289 293 289 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker4">[29]</xref>
###xml 791 795 791 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Broadbent1">[30]</xref>
###xml 796 800 796 800 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Farrall1">[31]</xref>
###xml 844 848 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Splansky1">[32]</xref>
###xml 1150 1154 1150 1154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Tsai1">[19]</xref>
###xml 54 59 <span type="species:ncbi:9606">Women</span>
###xml 129 134 <span type="species:ncbi:9606">women</span>
###xml 336 348 <span type="species:ncbi:9606">participants</span>
###xml 622 634 <span type="species:ncbi:9606">participants</span>
All samples in the discovery analysis derive from the Women's Genome Health Study (WGHS), a prospective cohort of North American women with phenotypes related to cardiovascular disease, extensive clinical and demographic data, blood samples at baseline, and ongoing genome-wide genotyping [29]. The current data derive from 17,296 WGHS participants with confirmed, self-reported European ancestry who were non-diabetic, not using lipid lowering therapy at baseline, and for whom genotype information was available. Within this group, 12,489 (72%) provided the baseline blood sample at least 8 hours after a meal and these participants constitute the fasting subsample. Samples in the replication analysis derive from PROCARDIS, an ongoing European study of premature coronary artery disease [30],[31], and from the Framingham Heart Study (FHS) [32], an ongoing, family-based longitudinal cohort designed to identify correlates with cardiovascular health, including subgroup analysis of the impact of plasma lipoprotein fractions. The FHS samples with NMR-based lipoprotein measurements for replication derive from the Offspring cohort within the FHS [19].
###end p 67
###begin title 68
Lipoprotein determinations
###end title 68
###begin p 69
###xml 199 202 193 196 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">100</sub>
###xml 282 286 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Ridker4">[29]</xref>
###xml 430 434 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Jeyarajah1">[33]</xref>
###xml 623 626 617 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Mora1">[4]</xref>
###xml 733 737 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Tsai1">[19]</xref>
In the WGHS, lipoprotein determinations were performed on baseline plasma samples that had been stored in liquid nitrogen (-170degreesC) since collection. LDL-C, HDL-C, triglycerides, ApoA1, and ApoB100 levels were all measured by direct assay and had low coefficients of variation [29]. NMR-based lipoprotein fractions were determined as described by proton NMR spectroscopy (LipoProtein-II assay, Liposcience Inc., Raleigh, NC) [33]. The coefficients of variation for these measures were also low (range 0.4-7.1%), except for the concentration of medium HDL particles (CV<30%) and IDL particle concentration (CV = 13.1%) [4]. PROCARDIS measurements were also performed with LipoProtein-II assays. Lipoprotein fractions for the FHS [19] samples were measured with the LipoProtein-I assay (Liposcience Inc. Raleigh, NC), which provides less accuracy for some measurements but is otherwise similar to LipoProtein-II.
###end p 69
###begin title 70
Genotyping
###end title 70
###begin p 71
###xml 887 888 887 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 893 895 893 895 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;6</sup>
###xml 1072 1076 1072 1076 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
###xml 1317 1321 1317 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Shiffman1">[34]</xref>
###xml 1435 1439 1435 1439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
Genotyping in the WGHS sample was performed using the HumanHap300 Duo "+" chips or the combination of the HumanHuman300 Duo and iSelect chips (Illumina, San Diego, CA) with the Infinium II protocol. In either case, the custom SNP content was the same; these custom SNPs were chosen without regard to minor allele frequency (MAF) to saturate candidate genes for cardiovascular disease as well as to increase coverage of SNPs with known or suspected biological function, e.g. disease association, non-synonymous changes, substitutions at splice sites, etc. For quality control, all samples were required to have successful genotyping using the BeadStudio v. 3.3 software (Illumina, San Diego, CA) for at least 98% of the SNPs. In the final dataset, SNPs were retained with MAF >1%, successful genotyping in 90% of the subjects, and deviations from Hardy-Weinberg equilibrium not exceeding P = 10-6 in significance. A total of 335,603 unique SNPs, of which 32,521 derive from the custom content, remained in the final data. Although assays for two non-synonymous SNPs at the APOE locus (19q13.32), rs429358 and rs7412, which determine ApoE isotype, failed in the design of the Illumina custom content, genotypes for these two SNPs were determined separately by an allele-specific, PCR based method (Celera, Alameda, CA) [34]. These additional SNPs are in linkage disequilibrium with SNPs in the Illumina panel. The targeted genotypes for APOE were included during the model selection procedures but not during the primary analysis to discover loci with genome-wide significant associations.
###end p 71
###begin title 72
Analytic methods
###end title 72
###begin p 73
###xml 144 148 144 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Purcell1">[35]</xref>
###xml 330 331 330 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 336 338 336 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 380 384 380 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Hirschhorn1">[36]</xref>
###xml 1165 1169 1165 1169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Frazer1">[37]</xref>
###xml 940 952 <span type="species:ncbi:9606">participants</span>
Primary analysis to discover loci with highly significant associations in the WGHS discovery cohort was performed by linear regression in PLINK [35] assuming an additive relationship between the number of copies of the minor allele of each SNP and the mean values of the adjusted lipoprotein measures. A conservative threshold of P<5x10-8 was assumed for genome-wide significance [36]. For each lipoprotein measure, a full adjustment was performed by linear regression using the clinical covariates: age at baseline (continuous), BMI (continuous), menopausal status (yes/no), current smoking status (yes/no), and use of hormone replacement therapy (yes/no). Concentrations of IDL particles, total LDL particles, medium HDL particles, triglycerides determined by NMR, and triglycerides determined by chemical assay were log-transformed before adjustment to approximate normality. Self-reported European ancestry was confirmed among the WGHS participants included in the primary analysis by clustering in a principal component analysis in PLINK with 1443 ancestry informative SNPs chosen for large Fst values (>0.4) among the HapMap CEU, YRI, and JPN+CHB populations [37]. Discrepancy between self reported European ancestry and the clustering pattern was observed only for 68 samples (<0.5%), and these samples were excluded from the analysis. In addition, genomic control parameters for the primary analysis were close to unity, ranging from 1.013-1.061. There was an estimated 80% power at the genome-wide significance level to detect effects explaining 0.23% and 0.32% of the variance in the adjusted lipoprotein measures respectively in the whole sample and the fasting subsample.
###end p 73
###begin p 74
###xml 782 783 782 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 788 790 788 790 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 94 106 <span type="species:ncbi:9606">participants</span>
The primary analysis also included association testing in a nested subset of 72% of the study participants who reported fasting for at least eight hours before providing the baseline blood sample. Analysis in this subset was expected to differ from the analysis in the whole sample by opposing trends: a loss of power due to reduced sample size was contrasted with possibly smaller variance among lipoprotein fractions that are influenced by prandial status, e.g. triglycerides. Because the majority of the sample was fasting, the association statistics in the two samples were expected to be highly correlated, and the statistical penalty for this additional testing in the Bonferroni framework was expected to be less than a factor of two. Our genome-wide significance threshold (P<5x10-8) was already smaller than required by correction for the number of SNPs tested by a factor of three, and justified including testing the fasting subset in the primary analysis.
###end p 74
###begin p 75
Once loci having at least one genome-wide significant association with at least one lipoprotein fraction had been identified, a non-redundant set of SNPs contributing to each lipoprotein fraction at each locus was constructed by forward-backward stepwise selection using the Bayesian Information Criterion (BIC) from among all genotyped locus SNPs within 100 kb of the locus genome-wide SNP associations. Separately, these model selection procedures were performed also at each of the candidate loci with the unadjusted, but possibly log-transformed, lipoprotein fractions to estimate the proportion of variance explained without adjustment.
###end p 75
###begin p 76
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Price1">[38]</xref>
###xml 543 544 543 544 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
To assess the degree to which the adjustment procedure or sub-European population stratification might influence the identification of genome-wide loci, we performed a secondary analysis to evaluate the sensitivity of the locus discovery procedure to the adjustments applied to lipoprotein fractions before association testing. First, we adjusted for all of the clinical covariates as well as ten eigenvectors corresponding to a principal component analysis of genotype frequency in EIGENSTRAT [38] among 64,208 SNPs chosen with inter-SNP LD r2<0.2 and followed by quantile normalization of the residuals. Second, we adjusted with all of the clinical covariates except BMI, either with or without inclusion of the eigenvectors and subsequent quantile normalization. Finally, we adjusted only for baseline age, again either with or without inclusion of the eigenvectors and subsequent quantile normalization. In an additional secondary analysis, the genome-wide association procedures were performed with lipoprotein fractions transformed and fully adjusted as for the primary analysis, including also log transformed triglyceride levels among the adjustment variables (see text).
###end p 76
###begin p 77
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-R1">[39]</xref>
###xml 266 270 266 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Storey1">[40]</xref>
###xml 300 305 <span type="species:ncbi:9606">human</span>
Additional analytic procedures, including the hierarchical clustering of loci according to effects on lipoprotein fractions, as well as the graphical representations were programmed in R [39], and included the False Discovery Rate analysis with the R-package QVALUE [40]. All annotations derive from human genome reference sequence hg18 (NCBI build 36.1), the UCSC Refseq as of October 27, 2008, and the dbSNP database (build 129) as represented by the UCSC database.
###end p 77
###begin title 78
Analysis in replication cohorts
###end title 78
###begin p 79
###xml 250 254 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Price1">[38]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-R1">[39]</xref>
###xml 822 826 822 826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Kathiresan3">[10]</xref>
###xml 982 986 982 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pgen.1000730-Barlera1">[20]</xref>
###xml 1049 1054 <span type="species:ncbi:9606">Human</span>
In the Framingham Heart Study (FHS) sample, residual lipoprotein fractions were created by adjusting for gender, age at exam lipoprotein fraction collection (continuous), age-squared (continuous), and the top ten principal components from EIGENSTRAT [38] before analysis. When appropriate, log transformations were applied to approximate normality before computing residuals. Association testing was performed in R [39] using a linear mixed effect regression model with a kinship matrix to account for the family structure in the sample. Genotype data were derived by imputation using MACH 1.0 () from raw genotypes collected with the Affymetrix (Santa Clara, CA) 500K array, and the regression models assumed a linear relationship between the dosage of the minor allele (ranging from 0 to 2) and the lipoprotein measures [10]. Only SNPs with high quality imputation measures (squared correlation of imputed and true genotype >0.3) were used in the analysis. In the PROCARDIS study [20], where genotype data derive from the Illumina (San Diego, CA) Human 1M platform representing a superset of the SNPs in the WGHS data, lipoprotein fractions were adjusted for case/control specific effects of age at baseline (continuous), gender, country of recruitment (Germany, Italy, Sweden, United Kingdom), self-reported hypertension (yes/no), diabetes (yes/no), current smoking status by questionnaire (yes/no), and statin therapy (yes/no). Regression models assumed a linear relationship between the number of copies of the minor allele and adjusted mean lipoprotein measure.
###end p 79
###begin title 80
Supporting Information
###end title 80
###begin p 81
Locus p-values for lipoprotein fractions with at least one SNP reaching genomewide significance at each of the candidate loci. All plots correspond to analysis in the whole sample except for locus 8p23.1, for which genomewide association was observed only in the fasting subsample as shown.
###end p 81
###begin p 82
(0.41 MB PDF)
###end p 82
###begin p 83
Click here for additional data file.
###end p 83
###begin p 84
###xml 218 239 218 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials and Methods</xref>
Primary loci clustered hierarchically according to Cartesian distance corresponding to whether ( = 1) or not ( = 0) there were associations with each of the lipoprotein fractions in the model selection procedures (see Materials and Methods).
###end p 84
###begin p 85
(0.02 MB PDF)
###end p 85
###begin p 86
Click here for additional data file.
###end p 86
###begin p 87
###xml 75 84 75 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pgen.1000730.s002">Figure S2</xref>
Dendorgram showing bierarchical relationships between loci clustered as in Figure S2.
###end p 87
###begin p 88
(0.01 MB PDF)
###end p 88
###begin p 89
Click here for additional data file.
###end p 89
###begin p 90
Normalized SNP effects (beta coefficients) from univariate regression models. All plots correspond to analysis in the whole sample except for locus 8p23.1, for which genome-wide association was detected only in the fasting subsample as shown. Locus SNPs are shown if they were retained in the model selection procedure for at least one lipoprotein fraction. Absence of shading indicates the univariate beta coefficient was not significant (p>0.05). A small black dot for some combinations of SNPs and lipoprotein fractions indicates genomewide significance for the univariate beta coefficient.
###end p 90
###begin p 91
(0.10 MB PDF)
###end p 91
###begin p 92
Click here for additional data file.
###end p 92
###begin p 93
Best genome-wide associations with the lipoprotein fractions at each candidate locus.
###end p 93
###begin p 94
(1.10 MB DOC)
###end p 94
###begin p 95
Click here for additional data file.
###end p 95
###begin p 96
Correlations between all pairs of lipoprotein fractions.
###end p 96
###begin p 97
(0.12 MB DOC)
###end p 97
###begin p 98
Click here for additional data file.
###end p 98
###begin p 99
Replication of WGHS candidate associations from whole sample in PROCARDIS and the Framingham Heart Study.
###end p 99
###begin p 100
(0.56 MB DOC)
###end p 100
###begin p 101
Click here for additional data file.
###end p 101
###begin p 102
Replication of WGHS candidate associations from fasting sub-sample in PROCARDIS and the Framingham Heart Study.
###end p 102
###begin p 103
(0.45 MB DOC)
###end p 103
###begin p 104
Click here for additional data file.
###end p 104
###begin p 105
Proportion of variance in fully adjusted lipoprotein fractions explained in the whole sample by genetic variation at the candidate loci.
###end p 105
###begin p 106
(0.15 MB DOC)
###end p 106
###begin p 107
Click here for additional data file.
###end p 107
###begin p 108
Proportion of variance in fully adjusted lipoprotein fractions explained in the fasting sub-sample by genetic variation at the candidate loci.
###end p 108
###begin p 109
(0.15 MB DOC)
###end p 109
###begin p 110
Click here for additional data file.
###end p 110
###begin p 111
Total proportion of variance explained by candidate loci for each of the unadjusted lipoprotein fractions.
###end p 111
###begin p 112
(0.04 MB DOC)
###end p 112
###begin p 113
Click here for additional data file.
###end p 113
###begin p 114
Sensitivity analysis for locus discovery procedure.
###end p 114
###begin p 115
(0.10 MB DOC)
###end p 115
###begin p 116
Click here for additional data file.
###end p 116
###begin p 117
Lipoprotein associations in the whole sample at loci in previous lipid fraction GWAS.
###end p 117
###begin p 118
(0.34 MB DOC)
###end p 118
###begin p 119
Click here for additional data file.
###end p 119
###begin p 120
Lipoprotein associations in the fasting sub-sample at loci in previous lipid fraction GWAS.
###end p 120
###begin p 121
(0.16 MB DOC)
###end p 121
###begin p 122
Click here for additional data file.
###end p 122
###begin p 123
###xml 221 225 221 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">APOE</italic>
The authors thank Marian Beekman (Leiden, Netherlands) for suggesting analysis with triglycerides-adjusted lipoprotein fractions. We are grateful to Dov Shiffman and James Devlin (Celera, Alameda, CA), for genotyping the APOE SNPs in the WGHS samples, and to James Otvos (Liposcience Inc., Rayleigh, NC), for lipoprotein determinations in the WGHS samples by NMR-based methods.
###end p 123
###begin title 124
References
###end title 124
###begin article-title 125
Low-density lipoprotein subclass patterns and risk of myocardial infarction.
###end article-title 125
###begin article-title 126
A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction.
###end article-title 126
###begin article-title 127
Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.
###end article-title 127
###begin article-title 128
###xml 159 164 <span type="species:ncbi:9606">women</span>
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.
###end article-title 128
###begin article-title 129
###xml 129 135 <span type="species:ncbi:9606">humans</span>
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.
###end article-title 129
###begin article-title 130
Newly identified loci that influence lipid concentrations and risk of coronary artery disease.
###end article-title 130
###begin article-title 131
Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides.
###end article-title 131
###begin article-title 132
LDL-cholesterol concentrations: a genome-wide association study.
###end article-title 132
###begin article-title 133
###xml 200 205 <span type="species:ncbi:9606">Women</span>
Genetic Loci Associated With Plasma Concentration of Low-Density Lipoprotein Cholesterol, High-Density Lipoprotein Cholesterol, Triglycerides, Apolipoprotein A1, and Apolipoprotein B Among 6382 White Women in Genome-Wide Analysis With Replication.
###end article-title 133
###begin article-title 134
Common variants at 30 loci contribute to polygenic dyslipidemia.
###end article-title 134
###begin article-title 135
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.
###end article-title 135
###begin article-title 136
Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.
###end article-title 136
###begin article-title 137
Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study.
###end article-title 137
###begin article-title 138
Serum-cholesterol and ABO and rhesus blood-groups.
###end article-title 138
###begin article-title 139
ABO and Lewis blood-groups and serum-cholesterol.
###end article-title 139
###begin article-title 140
###xml 149 154 <span type="species:ncbi:9606">Women</span>
###xml 164 169 <span type="species:ncbi:9606">Women</span>
Polymorphism in the CETP Gene Region, HDL Cholesterol, and Risk of Future Myocardial Infarction: Genome-wide Analysis Among 18 245 Initially Healthy Women From the Women's Genome Health Study Circ.
###end article-title 140
###begin article-title 141
Cloning and characterization of GRB14, a novel member of the GRB7 gene family.
###end article-title 141
###begin article-title 142
Structural basis for inhibition of the insulin receptor by the adaptor protein Grb14.
###end article-title 142
###begin article-title 143
Comparison of ultracentrifugation and nuclear magnetic resonance spectroscopy in the quantification of triglyceride-rich lipoproteins after an oral fat load.
###end article-title 143
###begin article-title 144
[PROCARDIS: A current approach to the study of the genetics of myocardial infarct].
###end article-title 144
###begin article-title 145
###xml 128 133 <span type="species:ncbi:9606">Women</span>
Loci related to metabolic-syndrome pathways including LEPR, HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study.
###end article-title 145
###begin article-title 146
Association of the BTNL2 rs2076530 single nucleotide polymorphism with Graves' disease appears to be secondary to DRB1 exon 2 position beta74.
###end article-title 146
###begin article-title 147
Association of the truncating splice site mutation in BTNL2 with multiple sclerosis is secondary to HLA-DRB1*15.
###end article-title 147
###begin article-title 148
Sarcoidosis is associated with a truncating splice site mutation in BTNL2.
###end article-title 148
###begin article-title 149
High incidence of propionic acidemia in greenland is due to a prevalent mutation, 1540insCCC, in the gene for the beta-subunit of propionyl CoA carboxylase.
###end article-title 149
###begin article-title 150
###xml 101 106 <span type="species:ncbi:9606">human</span>
WIPI-1alpha (WIPI49), a member of the novel 7-bladed WIPI protein family, is aberrantly expressed in human cancer and is linked to starvation-induced autophagy.
###end article-title 150
###begin article-title 151
Identification of structural mutations in the fifth domain of apolipoprotein H (beta 2-glycoprotein I) which affect phospholipid binding.
###end article-title 151
###begin article-title 152
###xml 43 46 <span type="species:ncbi:9606">men</span>
###xml 51 56 <span type="species:ncbi:9606">women</span>
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
###end article-title 152
###begin article-title 153
###xml 42 47 <span type="species:ncbi:9606">Women</span>
###xml 150 155 <span type="species:ncbi:9606">women</span>
Rationale, design, and methodology of the Women's Genome Health Study: a genome-wide association study of more than 25,000 initially healthy american women.
###end article-title 153
###begin article-title 154
Susceptibility to coronary artery disease and diabetes is encoded by distinct, tightly linked SNPs in the ANRIL locus on chromosome 9p.
###end article-title 154
###begin article-title 155
Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17.
###end article-title 155
###begin article-title 156
The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination.
###end article-title 156
###begin article-title 157
Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy.
###end article-title 157
###begin article-title 158
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study.
###end article-title 158
###begin article-title 159
PLINK: a tool set for whole-genome association and population-based linkage analyses.
###end article-title 159
###begin article-title 160
Genome-wide association studies for common diseases and complex traits.
###end article-title 160
###begin article-title 161
###xml 20 25 <span type="species:ncbi:9606">human</span>
A second generation human haplotype map of over 3.1 million SNPs.
###end article-title 161
###begin article-title 162
Principal components analysis corrects for stratification in genome-wide association studies.
###end article-title 162
###begin article-title 163
R: A language and environment for statistical computing.
###end article-title 163
###begin article-title 164
Statistical significance for genome-wide studies.
###end article-title 164
###begin article-title 165
###xml 64 69 <span type="species:ncbi:9606">human</span>
The fine-scale structure of recombination rate variation in the human genome.
###end article-title 165
###begin p 166
Alex Parker and Joseph Miletich are employees of Amgen.
###end p 166
###begin p 167
This work was funded by the Donald W. Reynolds Foundation (Las Vegas, NV), the Fondation LeDucq (Paris, France), the National Heart, Lung and Blood Institute (NHLBI; HL043851) and the National Cancer Institute (CA047988). J.O. was supported by the NHLBI (HL54776) and by the U.S. Department of Agriculture (under agreement no. 58-1950-9-001). Analysis in the Framingham Heart Study was supported by the NHLBI (HL54776). Analysis in PROCARDIS was funded by the British Heart Foundation, the EC Sixth Framework Programme (LSHM-CT- 2007- 037273), the Swedish Medical Research Council (8691), the Knut and Alice Wallenberg Foundation, and AstraZeneca AB. Other than Amgen, which provided genotyping and collaborative scientific support, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 167

